New York (December 21st, 2012) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse through its Aversion and Impede Technologies, is down sharply in mid-day trading today, extending its losses from the previous trading sessions.
ACUR is currently trading 4.63% lower at $2.27 on volume of 297,948, which is well below the daily average volume of 805,619. The stock has fallen more than 12% in the last three trading sessions.
ACUR has fallen sharply in the last three days even as the company announced that it filed an Investigational New Drug Application with the FDA to allow clinical testing of its hydrocodone bitartrate with acetaminophen formulated with Aversion® Technology.
Find out more about ACUR by getting the free full report here:
ALXA had rallied more than 13% on Thursday. The stock is down nearly 5% to $5.91 in trading currently on above average volume of 1.30 million.
ALXA has been struggling to break through $6.25 resistance level. If the stock breaks through this level, a strong bullish trend will be established.
ALXA last week announced that a European Union panel recommended approval of its Adasuve.